Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cells

Keith Stewart • 9 Dec 2017
ASH 2017
General Multiple Myeloma Antibodies CAR-T
ASPIRE BMA117159

The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, presented cutting-edge updates in hematology. Discover the top picks of this year’s meeting with Keith Stewart, MD, ChB, of the Mayo Clinic, Scottsdale, AZ. Dr Stewart highlights Phase III trials, antibody-drug conjugates and CAR T-cells, emphasizing key data showing the promise of particular therapies. He also discusses where he forsees CAR T-cell therapy moving in the next year.

More from Keith Stewart

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
10:38
Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan et al. • 27 Mar 2022
11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Faith Davies et al. • 26 Mar 2022
3:09
Immunotherapy in myeloma - where are we?
Keith Stewart • 30 Apr 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals